JOHNSON & JOHNSON is 2.0x more valuable than Merck & Co., Inc. by market capitalization ($573.98 B vs $293.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | JNJ | MRK |
|---|---|---|
| Market cap | $573.98 B | $293.16 B |
| US-listed rank | #20 | #44 |
| Revenue (latest FY) | $94.19B | $65.01B |
| Net income (latest FY) | $26.80B | $18.25B |
| Net margin | 28.5% | 28.1% |
| P/E (trailing FY) | 21.4 | 16.1 |
| SEC filings | 984 | 996 |
JOHNSON & JOHNSON is 2.0x more valuable than Merck & Co., Inc. by market capitalization ($573.98 B vs $293.16 B).
In their latest fiscal years, JOHNSON & JOHNSON reported $94.19B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: JOHNSON & JOHNSON and Merck & Co., Inc., or browse the full rankings.